Results 131 to 140 of about 1,181,836 (211)

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

Inflammatory Bowel Diseases
Dose escalation of IV infliximab is an option for inflammatory bowel disease (IBD) patients who lose response after induction therapy. However, as yet, there is limited data for CT-P13 subcutaneous (SC) infliximab (CT-P13 SC) dose escalation in IBD
S. Danese, J. Colombel, Stephen B. Hanauer, W. Sandborn, Bruce E. Sands, Stefan Schreiber, Sang Joon Lee, Sung Hyun Kim, Yunju Bae, Sun Hee Lee, S. Lee, J. Lee, Jong Min Kim, S. Yang, Jimin Lee, G. Park, Ju Hyun Lee   +16 more
semanticscholar   +1 more source

Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Health Economics Review
Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases.
Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour, Joachim Marti   +3 more
doaj   +1 more source

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists [PDF]

, 2015
Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs.
Baji, Petra, Brodszky, Valentin, Golovics, Petra A., Gulácsi, László, Lakatos, Péter L., Lovász, Barbara D., Péntek, Márta, Rencz, Fanni   +7 more
core  

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

Is CT-P13 As Effective As Infliximab In Controlling Pain In Adult Patients With Rheumatoid Arthritis? [PDF]

, 2020
OBJECTIVE: The objective of this selective EBM review is to determine whether or not CTP13 is as good as infliximab in controlling pain in adult patients with rheumatoid arthritis. STUDY DESIGN: A review of three double-blind randomized controlled trials
Nazareno, Emily
core   +1 more source

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

Drug Design, Development and Therapy, 2017
Andrea Becciolini,1 Maria Gabriella Raimondo,2 Chiara Crotti,2 Elena Agape,2 Martina Biggioggero,2 Ennio Giulio Favalli1 1Department of Rheumatology, 2Department of Clinical Sciences and Health Community, University of Milan, Division of Rheumatology ...
Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG   +5 more
doaj  

Desmoplastic Small Round Cell Tumor of Stomach

Case Reports in Gastrointestinal Medicine, 2013
Desmoplastic small round cell tumor (DSRCT) is an extremely uncommon, highly aggressive, and malignant mesenchymal neoplasm of undetermined histogenesis. Less than 200 case reports have been documented in literature so far.
Ahmed Abu-Zaid, Ayman Azzam, Asma AlNajjar, Hussa Al-Hussaini, Tarek Amin   +4 more
doaj   +1 more source

Biosimilar CT-P13 in treating ulcerative colitis in the real world [PDF]

Minerva Gastroenterology, 2017
RIBALDONE, Davide Giuseppe, Astegiano, Marco   +1 more
openaire   +2 more sources

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

BMC Rheumatology
Background CT-P13 SC, a new subcutaneous (SC) formulation of biosimilar infliximab (IFX), was approved by the European Medicines Agency in 2020 for the treatment of radiographic axial spondyloarthritis (axSpA) in adult patients.
Xenofon Baraliakos, Ye Eun Lee, Soyeon Park, Young Nam Lee, Isabel Truman, Molly Edwards, Emily Quiñones, Raj Sengupta   +7 more
doaj   +1 more source

CT-P13 biosimilar is non-inferior to infliximab [PDF]

Nature Reviews Gastroenterology & Hepatology, 2019
openaire   +2 more sources